Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Neuropsychiatric Symptoms in ASD with Atopy
NCT04535817Phase 1Withdrawn
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of omalizumab in Autism Spectrum Disorder (ASD), sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Social Responsiveness Scale Edition 2 at Week 48, Aberrant Behavior Checklist at Week 48 and 1 more. Planned start Jan 2021; status: withdrawn.
02
Drugs
omalizumab
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04535817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535817.